55 results
S-8
EX-99.2
NTBL
Notable Labs Ltd
19 Apr 24
Registration of securities for employees
4:56pm
and shall be subject to a vesting schedule, and may be further subject to any performance goals and measurements as may be determined by the Board. Unless
8-K
EX-99.1
NTBL
Notable Labs Ltd
12 Apr 24
Notable Labs Reports 2023 Financial Results and Provides a Business Update
8:44am
to, express or implied statements regarding Notable’s future operations and goals; the potential benefits of any therapeutic candidates or platform
8-K
EX-99.1
NTBL
Notable Labs Ltd
9 Apr 24
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
5:20pm
but not limited to, express or implied statements regarding Notable’s future operations and goals; the potential benefits of any therapeutic candidates
8-K
EX-99.1
NTBL
Notable Labs Ltd
8 Apr 24
Other Events
12:15pm
future operations and goals; the potential benefits of any therapeutic candidates or platform technologies of Notable; the timing of any clinical
8-K
EX-99.1
2ewydluizsn
22 Feb 24
Other Events
8:15am
DEF 14A
6vmuy
16 Feb 24
Definitive proxy
9:00am
PRE 14A
wcvii28
5 Feb 24
Preliminary proxy
5:00pm
8-K
EX-99.1
q2vpahlu u0e8
18 Dec 23
Other Events
8:15am
8-K
EX-99.1
l79476hrys5r qm
14 Nov 23
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023
12:00am
8-K
EX-99.1
hmgrm67ppqpvnl4
16 Oct 23
Notable Labs Closes Merger Transaction With VBL Therapeutics
4:05pm
425
2wdojg k1
4 Oct 23
Business combination disclosure
4:33pm
425
EX-99.1
5cm7qb4w
6 Sep 23
Business combination disclosure
8:17am
8-K
EX-99.1
k7vra4vx
6 Sep 23
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
8:13am
424B3
64kcrwr f1m0
5 Sep 23
Prospectus supplement
6:02pm
425
EX-99.1
gav8 4h8wngv69sxb
14 Aug 23
Business combination disclosure
8:06am